Indian Journal of Medical and Paediatric Oncology

LinksSchließen

Referenz

Wu YL, Zhang L, Kim DW. et al.
Phase Ib/II study of Capmatinib (INC280) plus Gefitinib after failure of epidermal growth factor receptor (EGFR) inhibitor therapy in patients with EGFR-mutated, MET factor-dysregulated non-small-cell lung cancer.

J Clin Oncol 2018;
36 (31) 3101-3109

Bibliographische Angaben herunterladen

Aufrufen in: